Overview of Keto B

Property	Description
Active ingredient	Beclometasone and Ketoconazole
Form	Topical cream, ointment, or solution
Pharmacological Class	Topical Corticosteroid and Azole Antifungal
Product Type	Fixed-dose combination (Dual-action)
Origin	Synthetic compound

What Type of Medicine is Keto B?

Keto B is a prescription medicine formulated for topical dermatological application, recognized as a fixed-dose combination product. This specific formulation is classified as a dual-action medicine, a strategy used for managing skin issues where both inflammation and fungal proliferation occur simultaneously. The preparation delivers two distinct therapeutic agents within a single pharmaceutical preparation, distinguishing it from treatments requiring separate applications of a corticosteroid and an antifungal.

Composition and Pharmacological Identity

The medicinal identity of Keto B is defined by its two primary active ingredients: Beclometasone and Ketoconazole. Beclometasone, a synthetic compound, belongs to the Topical Corticosteroid class, providing recognized anti-inflammatory and antipruritic effects. Ketoconazole is an azole antifungal agent, known for its ability to inhibit ergosterol synthesis, a key fungal cell function. This specific combination is clinically recognized for its use in managing certain irritated, itchy skin conditions.

General Purpose of the Dual-Action Formulation

The general purpose of this unique combination is to execute both rapid symptomatic relief and fundamental pathogen control. The Beclometasone component provides immediate anti-inflammatory action, reducing swelling and calming the intense itching sensations. Concurrently, the Ketoconazole executes its antifungal action to inhibit the growth of susceptible fungi and yeasts. Combining these two distinct pharmacological classes in one product simplifies the treatment regimen while optimizing the therapeutic outcome by ensuring both key pathological factors are addressed. This integrated mechanism of effect aims to resolve the underlying cause of microbial irritation while rapidly mitigating the distressing symptoms.

Regulatory References

NIH Drug Record - Ketoconazole

Therapeutic Uses of Keto B

What Keto B Treats: Main Uses and Benefits

Keto B is generally considered relevant as a combination therapy when superficial fungal skin infections present with a significant inflammatory component. Its primary value is the dual-action benefit that supports the management of the underlying pathogen and helps ease associated acute symptoms. The antifungal component is indicated for treating conditions like Tinea corporis, Tinea cruris, Tinea pedis, Cutaneous Candidiasis, and Seborrheic dermatitis.

It is commonly used for Tinea infections and Cutaneous Candidiasis when the infection is marked by intense visible symptoms like skin redness and swelling. This application is relevant for easing symptoms that interfere with daily comfort, particularly when fungal infections present with pronounced irritation and itching. The supportive benefit may assist in easing the burden of these acute symptoms, which supports the patient during difficult episodes.

Quick Fact: Symptomatic Relief Domains
This combination is generally applied in contexts marked by increased discomfort and is relevant for managing symptom clusters that may become intense or disruptive by targeting both the pathogen and the resulting inflammation.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Keto B is subject to strict eligibility rules documented in official regulatory labeling. Use is contraindicated (prohibited) for individuals with a known hypersensitivity to the active ingredients (Ketoconazole or Beclometasone) or any excipient in the formulation. Use is also strictly prohibited in the presence of viral skin infections, such as chickenpox or herpes simplex. Regulatory labeling further restricts use in patients with rosacea, perioral dermatitis, or simple itching (pruritus) without an underlying fungal or inflammatory cause.

Regarding specific populations, safety and effectiveness have not been established for children under 12 years of age. For those under 17, use is generally not recommended due to the presence of the corticosteroid component. In pregnancy, the medicine is classified as Category C, meaning use is only permitted if the potential benefit outweighs the potential risk to the fetus. Nursing mothers are directed to avoid application to the breast area. The product is not intended for ophthalmic (eye) use and must be used exclusively for topical application.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of this topical fixed-dose combination product is governed by the potential for systemic absorption of its Beclometasone (corticosteroid) component, as noted in regulatory documentation. The negligible systemic absorption of the Ketoconazole component after topical application officially excludes the severe drug-drug contraindications associated with its oral form.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Pharmacokinetic	Strong CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat)	Increases the systemic exposure of the Beclometasone component, enhancing the potential for corticosteroid-related effects.
Pharmacodynamic	Other Corticosteroids (topical or systemic)	Risk of additive glucocorticoid effects, increasing the potential for systemic adverse reactions.

Interaction-Related Constraints

Official labeling does not document any formal contraindications for the topical product itself. Restrictions focus on avoiding co-administration with other steroids due to additive effects, and caution is noted with strong CYP3A4 inhibitors. Regulatory documents note that the risk of systemic consequences may be elevated in pediatric patients and those with hepatic impairment due to reduced clearance capacity. There are no mandatory timing separation rules or documented interactions with food, alcohol, or herbal supplements for this topical formulation.

Mechanism of Action

Ontology: How Keto B Works — Mechanism of Action

Keto B utilizes a dual pharmacodynamic mechanism involving its two components. The antifungal component, Ketoconazole, acts as an inhibitor of the fungal enzyme cytochrome P450 14alpha-demethylase (CYP51A1) in the ergosterol biosynthesis pathway. This mechanistic cascade prevents the formation of ergosterol, an essential component of the fungal cell membrane, leading to structural impairment, compromised integrity, and fungal cell death.

The corticosteroid component, Beclomethasone dipropionate, functions as an agonist for intracellular glucocorticoid receptors (GRs) within host cells. Activation of the GR complex modulates gene transcription, leading to the suppression of pro-inflammatory gene expression and the inhibition of key inflammatory mediators like prostaglandins. The resulting system-level physiological modulation includes vasoconstriction and a marked dampening of the local immune response. The two distinct mechanisms act concurrently, influencing the overall physiological process.

Dosage and Administration Information

Official Administration Guidelines: Keto B

The dual-action medicine Keto B (Beclometasone and Ketoconazole) is used according to specific instructions for application route, frequency, and duration. The administration of this product is strictly limited to Topical (Cutaneous) use on the skin.

Administration Scope and Frequency

Feature	Official Guideline
Route of Administration	Topical / Cutaneous Administration
Dosing Schedule	Application of a thin layer to the affected area and its immediate surrounding skin
Standard Frequency	Typically Once Daily or Twice Daily
Population	Primarily established for use in Adults

The application frequency is determined by the specific condition being addressed. For most fungal infections, such as tinea corporis and tinea cruris, a Once Daily frequency is standard. However, for conditions like seborrheic dermatitis, the application is recommended Twice Daily. The safety and effectiveness of the Ketoconazole component have not been established in pediatric patients.

Course Duration and Procedural Conditions

Treatment with Keto B is limited to short-term, defined courses. The duration for conditions such as tinea corporis and tinea cruris is typically two weeks, while tinea pedis requires up to six weeks of application. If no clinical clearing is observed after the prescribed course, the diagnosis must be reassessed.

This product is restricted to external use only and must not be applied to the eyes or mucous membranes. Additionally, it is generally advised against covering the treated area with an occlusive dressing unless a healthcare provider specifically directs it.

Recent Clinical Evidence

Research evidence / Overview of Studies for Keto B

Evidence for Use in Inflamed Fungal Skin Infections

Research examined the approach of combining an antifungal agent (Ketoconazole) with an anti-inflammatory agent (Beclometasone) for conditions like Tinea infections and Cutaneous Candidiasis, particularly when they presented with symptoms of heightened inflammation such as noticeable redness, swelling, and itching. Research has explored the use of this approach through short-term Randomized Controlled Trials (RCTs) and comparative studies.

In these studies, researchers monitored several key outcomes related to physical discomfort and the underlying cause of the skin condition. They used established scales to measure changes in visible signs like redness and swelling, which are outcomes linked to inflammatory or irritative states. Concurrently, laboratory tests were used to monitor the presence of the fungal pathogen itself, contributing to the broader evidence landscape. Findings from trials exploring this dual-action concept report patterns observed in the initial symptom scores over defined time intervals.

Evidence for Use in Seborrheic Dermatitis

Research has also explored the use of the medicine’s components for conditions such as Seborrheic Dermatitis, which is characterized by fluctuating or episodic manifestations. The evidence base includes comparative studies and RCTs, frequently focusing on the Ketoconazole antifungal component or other combination products. Studies focused on episodes where symptoms become more noticeable, measuring symptom severity scores related to physical discomfort, such as redness, scaling, and itching.

Limitations and Research Gaps

Research dedicated to the specific Beclometasone-Ketoconazole combination is limited compared to available studies on the broader class of combined antifungal-corticosteroid topical treatments, as dedicated, large-scale RCTs for this exact formulation are less frequently found in core academic summaries. A key limitation is that sample sizes were often modest, and follow-up durations were limited across the core comparative trials.

Consequently, there is limited information for long-term outcomes, and there is limited information for long-term outcomes regarding the durability of measured symptom patterns. Studies observing responses over defined time intervals do not provide sufficient data to characterize the long-term observation of these conditions or the likelihood of symptoms recurring months later. Additionally, comparative evidence specifically for the Beclometasone-Ketoconazole formulation against other combination products is limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Keto B (FAQ)

Q: How quickly can I expect Keto B to start working?

A: According to the official product information, the Beclometasone component is included to provide rapid symptomatic relief, helping to reduce uncomfortable symptoms like swelling and itching quickly. Studies on the medicine monitor changes in visible signs and symptom scores are monitored over defined time intervals in research.

Q: Is it normal to feel a bit tired when first starting Keto B?

A: Tiredness or fatigue is not listed as a Common or Uncommon side effect in official regulatory documents. While the medicine is applied topically, rare and serious adverse effects are linked to the corticosteroid component's potential for systemic effects.

Q: Does Keto B cause any long-term health issues mentioned in official documents?

A: Official documents associate specific dermatological changes like skin atrophy (thinning) and striae (stretch marks) with prolonged and intensive treatment. Regarding the underlying condition, research evidence is limited on very long-term outcomes and the durability of symptom patterns after stopping the medicine.

Q: What should I do if I think I missed a dose of Keto B?

A: Regulatory guidance for a missed dose is typically to apply it as soon as it is remembered. However, if it is already close to the time for your next scheduled application, it is generally recommended to skip the missed dose and resume the regular schedule.

Q: Why does the packaging for Keto B include a specific warning about a certain population?

A: The regulatory label includes specific safety constraints for pediatric patients (children and adolescents), noting their higher susceptibility to potential systemic effects like HPA axis suppression due to the corticosteroid component being absorbed through the skin.

Q: Can I drink alcohol while using Keto B, according to official information?

A: Official regulatory documents state there are no documented interactions with food, alcohol, or common herbal supplements for this topical formulation. This is due to the very low level of systemic absorption of the active ingredients when applied to the skin.

Q: How does Keto B affect things like driving or operating machinery?

A: Due to the medicine being for topical administration and its negligible systemic absorption, official regulatory documents do not list any known impact on a person's ability to drive or operate machinery. The medicine is not expected to cause drowsiness or impair motor skills.

Q: What is the purpose of the inactive ingredients in Keto B?

A: Inactive ingredients, also called excipients, are listed in regulatory documents because they are crucial components of the preparation. They are used to stabilize the product, help the active ingredients be delivered to the skin, and form the cream or ointment base.

Q: Is Keto B considered a controlled substance?

A: No, Keto B, in its topical fixed-dose combination form, is not classified as a controlled substance by regulatory bodies.

Q: Why do some people experience mild dizziness with Keto B?

A: Dizziness is not classified as a Common or Uncommon adverse reaction in official product information. Any potential dizziness would be considered an unlisted or rare adverse effect tied to the possible systemic absorption of the corticosteroid component.

Q: Can people with mild liver problems safely use Keto B?

A: Regulatory documents note that the risk of systemic effects may be elevated in individuals with hepatic impairment (liver problems). This is because the body's ability to clear the medicine may be reduced, which is a point of caution noted by regulators.

Q: Is Keto B known to cause weight changes?

A: Weight changes are not listed as a common or uncommon side effect of the topical treatment. However, very rare and serious systemic effects related to the corticosteroid component, such as Cushing’s syndrome, can be associated with weight gain.

Q: Does Keto B make you more sensitive to the sun?

A: Regulatory documents do not specifically list increased sensitivity to the sun (photosensitivity) as a documented adverse effect of Keto B.

Q: Is Keto B used to treat symptoms, or does it address the underlying condition?

A: Keto B is officially described as a dual-action medicine intended to address both factors. The Beclometasone component provides immediate symptom relief (anti-inflammatory), while the Ketoconazole component provides pathogen control (antifungal) to inhibit the growth of susceptible fungi.

Q: What happens if I stop taking Keto B suddenly?

A: Official instructions specify that treatment should be limited to short-term, defined courses. Stopping a product containing a corticosteroid component suddenly is generally not advised, as it may lead to a relapse of symptoms; the prescribed course duration should be followed as described in the official instructions.

Q: What are the official guidelines regarding using Keto B during pregnancy or breastfeeding?

A: Official guidelines classify the medicine as Category C in pregnancy, meaning it is only used if the benefit outweighs the potential risk. For nursing mothers, regulatory documents direct them to avoid application to the breast area.

Q: How common are the rare side effects of Keto B described in the leaflet?

A: Official documents define frequency categories based on reported data. For example, Uncommon effects occur in ge 1/1,000 to <1/100 users. Adverse reactions are classified based on the reported rate in clinical trials and postmarketing reports.

How should Keto B be stored and disposed of?

How to Store and Dispose of Keto B Cream

The storage and disposal of this topical combination medicine must follow conditions defined in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature: 20^circC to 25^circC (68^circF to 77^circF) as specified for its active components.
Protection	Keep the medicine in a closed container and shield it from heat, moisture, and direct light.
Prohibition	Do not allow the product to freeze.

Handling and Disposal

It is officially mandated to keep this and all medications out of the reach of children. Unused or expired Keto B cream must be discarded properly; official guidance instructs users to ask a pharmacist or healthcare professional for details on correct disposal methods, as the product should not be placed in household waste or flushed down the drain.

Keto B